Improving Clinical Outcomes Through PARP Inhibition in Patients with Advanced Ovarian Cancer
| Overview / Abstract: |
This digital algorithm offers stepwise practical guidance to prepare oncologists to employ PARP inhibitors effectively and safely in eligible ovarian cancer patients. Due to the many patient characteristics that determine eligibility, the algorithm supports branching logic in the context of patient disease status, response to chemotherapy, molecular profile, and tolerability. This activity is intended for medical oncologists, gynecologist oncologists, surgical oncologists, oncology nurses and other healthcare providers who care for patients with ovarian cancer, including physician assistants and nurse practitioners. Upon completion of this activity, participants will be able to: |
|
Expiration |
Nov 05, 2021 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Monograph, Online, Webinar / Webcast / Video, Workbook |
|
Credits / Hours |
1.25 |
|
Accreditation |
ACCME, ANCC |
|
Is This Activity Certified for "Live" Credit? |
YES |
|
Presenters / Authors / Faculty |
Summer B. Dewdney, MD Bradley Monk, MD, FACOG, FACS |
|
Activity Specialities / Related Topics |
Education / Teaching, Infertility, OB/GYN / Women's Health, Oncology / Cancer / Radiation Therapy, Sexual Issues |
|
Sponsors / Supporters / Grant Providers |
Provided by Rush University Medical Center and the Academy for Continued Healthcare Learning (ACHL). Supported by an educational grant from GlaxoSmithKline. |
|
Keywords / Search Terms |
ACHL Ovarian Cancer, CME, CE, PARP Inhibition, Newly diagnosed Ovarian Cancer, Recurrent Ovarian Cancer, PARPi algorithm, PARPi adverse events, ACHL, Rush University, Bradley Monk, Summer Dewdney, Niraparib, Olaparib, Rucaparib, Bevacizumab, ARIEL4, ATHENA, FIRST, DUO-O, MEDIOLA, TOPACIO, KEYLYNK-001, SOLO-2, NOVA, ARIEL 3, GSK Free CE CME Live CE CME |
|